The sale of the Alzheimer's medicine Leqembi has generated 6.3 billion yen, equivalent to around 450 million kronor, during the second quarter. This is evident from preliminary global figures.
The sale increased by 120 percent compared to the previous quarter and gives Bioarctic, whose discovery is the basis for the product, approximately 43 million kronor in royalties, the company writes in a press release.
The medicine was developed by American Biogen and Japanese Eisai. It began selling in Japan in December and has been sold previously in, among other places, the USA.
The EU, unlike several other countries, has so far refused to approve Leqembi – which is used to treat mild dementia resulting from Alzheimer's. In its decision on July 25, the European Medicines Agency EMA wrote that the treatment's benefits do not outweigh its risks.
Bioarctic writes in the press release that it is, while waiting for European approval, preparing a launch in the Nordic countries together with Eisai.
